Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2024.
- The company expects to fund the share repurchase program using a combination of existing cash reserves and future cash flows.
- Total revenues were $167.1 million in the first quarter of 2024, versus $160.3 million reported for the first quarter of 2023.
- First quarter 2024 iovera° net product sales were $5.0 million, versus $4.0 million reported for the first quarter of 2023.
- Adjusted EBITDA was $44.6 million in the first quarter of 2024, compared to $41.9 million in the first quarter of 2023.